Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has entered into a second supply agreement to expand the supply of Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]) as part of its commitment to help patients with pneumococcal disease.
Subscribe to our email newsletter
The company intends to manufacture total of 480 million doses of the vaccine, which is in line with its commitment made in March 2010 to supply up to 300 million doses of the vaccine under the auspices of the Advance Market Commitment (AMC) for pneumococcal vaccines.
The AMC program piloted by the GAVI Alliance, aims to ensure an affordable and stable supply of pneumococcal vaccines at a discounted price, besides developing and expanding the manufacturing capacity for vaccines specifically for the world’s poorest countries.
GAVI has financed the supply of pneumococcal vaccines for five donor countries including Italy, the UK, Canada, the Russian Federation, Norway.
Pfizer Vaccines president Mark Swindell said the company is happy to extend access to their vaccine to advance public health
"Public-private partnership programs like the AMC are vital to accelerating the availability of affordable vaccines, faster than ever before, to those children who are most vulnerable," Swindell added.